Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02134665

Enrollment

200

Registered

2014-05-09

Start date

2013-05-31

Completion date

2014-05-31

Last updated

2014-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arbitrary Restriction Polymorphism 1

Keywords

Vancomycin, severe acute pancreatitis, Creatinine clearance

Brief summary

The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent.

Detailed description

The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent. After reviewing more than 6000 clinical charts of patients who received vancomycin therapy and whose serum vancomycin level was monitored between January 2010 and December 2013, we identified 212 patients who also had diagnosed as severe acute pancreatitis (SAP group), and 98 patients who also had diagnosed as pneumonia (pneumonia group) at that time. The fluorescence polarization immunoassay method was used to measure vancomycin serum trough concentrations in these patients 30 min before the next administration. Using these measurements, we calculated the pharmacokinetic parameters using the Bayesian estimator.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* age 18-85years old * vancomycin use ≥ 3days

Exclusion criteria

* age \<18years old or \>85 years old * vancomycin use \< 3days

Design outcomes

Primary

Measure	Time frame	Description
vancomycin serum trough concentrations in these patients just prior to the next vancomycin serum trough concentrations was measured	patients will be followed for the duration of hospital stay, an expected average of 5 weeks	vancomycin serum trough concentrations was measured in patients just prior to the next dose at steady-state conditions (approximately after the fourth dose).

Secondary

Measure	Time frame
the pharmacokinetic parameters was calculated using the Bayesian estimator.	patients will be followed for the duration of hospital stay, an expected average of 5 weeks

Countries

China

Contacts

Primary ContactJuan He

hejuanwin@126.com86-21-64370045

Outcome results